Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism CD33 inhibitors(Myeloid cell surface antigen CD33 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 3 | US | 22 Jan 2015 | |
Myelodysplastic Syndromes | Phase 3 | DE | 22 Jan 2015 | |
Acute Myeloid Leukemia | Phase 2 | ES | 16 Jun 2016 | |
Acute Myeloid Leukemia | Phase 2 | DE | 16 Jun 2016 | |
Acute Myeloid Leukemia | Phase 2 | US | 16 Jun 2016 | |
Acute Myeloid Leukemia | Phase 2 | IT | 16 Jun 2016 | |
Relapsing acute myeloid leukemia | Phase 2 | US | 13 Sep 2012 |
Phase 1/2 | 49 | (Phase I Dose Escalation: BI 836858 20 mg + Decitabine (Intensive)) | whwwwtwayp(staatgqtoj) = xolwzifinp hxngpkkkdg (bnvnuyoqsf, rgtdpjkutr - kjtfinemxc) View more | - | 19 Mar 2024 | ||
(Phase I Dose Escalation: BI 836858 40 mg + Decitabine (Intensive)) | whwwwtwayp(staatgqtoj) = zebkhirmcj hxngpkkkdg (bnvnuyoqsf, ygcvdybkvk - apgemaewfx) View more |